FDA Committee Unanimously Recommends New Subcutaneous Dose of Rituxan

An FDA advisory committee unanimously voted to recommend approval of Genentech’s new subcutaneous formulation of Rituxan for several blood cancer indications.
Source: Drug Industry Daily